Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 6:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 71 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: allogeneic tumor cell vaccine Clear all
Completed Phase 2 Interventional Results available

Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer

NCT00654030
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
1650-G Vaccine
Drug
Lead sponsor
Edward Hirschowitz
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Danville, Kentucky • Lexington, Kentucky • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Oct 1, 2026, 6:34 AM EDT
Completed Phase 1 Interventional

Study of Colon GVAX and Cyclophosphamide in Patients With Metastatic Colorectal Cancer

NCT00656123
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
Colon GVAX, cyclophosphamide
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 1, 2026, 6:34 AM EDT
Active, not recruiting Phase 4 Interventional

Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

NCT03023631
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Recombinant Human Papillomavirus Nonavalent Vaccine
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 1, 2026, 6:34 AM EDT
Terminated Phase 3 Interventional

Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients

NCT00133224
View directory record Official record
Conditions
Prostate Cancer
Interventions
Immunotherapy allogeneic GM-CSF secreting cellular vaccine, Chemotherapy (docetaxel and prednisone)
Biological · Drug
Lead sponsor
Cell Genesys
Industry
Eligibility
18 Years and older · Male only
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
43
States / cities
Anchorage, Alaska • Fort Smith, Arkansas • Loma Linda, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2008 · Synced Oct 1, 2026, 6:34 AM EDT
Terminated Phase 1Phase 2 Interventional

Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers

NCT00095862
View directory record Official record
Conditions
Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
allogeneic GM-CSF-secreting breast cancer vaccine, recombinant interferon alfa, cyclophosphamide
Biological · Drug
Lead sponsor
Wiseman Research Initiatives LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
3
States / cities
Glendale, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 1, 2026, 6:34 AM EDT
Completed Phase 2 Interventional Results available

Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer

NCT00970203
View directory record Official record
Conditions
Cancer of Prostate, Cancer of the Prostate, Neoplasms, Prostate, Neoplasms, Prostatic, Prostate Cancer, Prostate Neoplasms, Prostatic Cancer
Interventions
androgen ablation (AA), DC1 vaccine
Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Oct 1, 2026, 6:34 AM EDT
Completed Phase 1Phase 2 Interventional

Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer

NCT00050323
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Allogeneic DCs and Autologous RCC Tumor Derived Cells
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Oct 1, 2026, 6:34 AM EDT
Terminated Phase 1 Interventional

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

NCT05395052
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
Interventions
FT536, Cyclophosphamide, Fludarabine, IL-2, Avelumab, Pembrolizumab, Nivolumab, Atezolizumab, Trastuzumab, Cetuximab, Amivantamab
Drug · Combination Product
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Scottsdale, Arizona • Los Angeles, California • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 1, 2026, 6:34 AM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Treatment for Hormone Refractory Prostate Cancer

NCT00105053
View directory record Official record
Conditions
Prostate Cancer
Interventions
HyperAcute-Prostate Cancer Vaccine
Biological
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
19 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 1, 2026, 6:34 AM EDT
Completed Phase 2 Interventional

Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer

NCT00002475
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer, Malignant Mesothelioma, Pancreatic Cancer
Interventions
allogeneic tumor cell vaccine, autologous tumor cell vaccine, recombinant interferon alfa, recombinant interferon gamma, sargramostim, cyclophosphamide
Biological · Drug
Lead sponsor
St. Vincent Medical Center - Los Angeles
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 1, 2026, 6:34 AM EDT
Terminated Phase 1 Interventional

Immunization of Patients With Non Small Cell Lung Cancer (NSCLC)

NCT00793208
View directory record Official record
Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
semi-allogeneic human fibroblasts (MRC-5) transfected with DNA
Biological
Lead sponsor
Theresa Whiteside, PhD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 1, 2026, 6:34 AM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Treatment for Advanced Malignant Melanoma

NCT00300612
View directory record Official record
Conditions
Malignant Melanoma
Interventions
HyperAcute-Melanoma Vaccine
Biological
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 1, 2026, 6:34 AM EDT
Withdrawn Phase 1 Interventional

Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA

NCT02211027
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
Semi-allogenic human fibroblast (MRC-5) transfected with DNA
Biological
Lead sponsor
Robert Ferris
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Oct 1, 2026, 6:34 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma

NCT00625755
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Electrofusion DC vaccine
Biological
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 1, 2026, 6:34 AM EDT
Completed Phase 2 Interventional Results available

Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast Cancer

NCT00399529
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Allogeneic GM-CSF-secreting breast cancer vaccine, Trastuzumab, Cyclophosphamide
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Oct 1, 2026, 6:34 AM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Treatment for Surgically Resected Pancreatic Cancer

NCT00255827
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
HyperAcute-Pancreatic Cancer Vaccine
Biological
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 1, 2026, 6:34 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy, Chemotherapy, and GM-CSF in Treating Patients With Advanced Pancreatic Cancer

NCT00002773
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
allogeneic tumor cell vaccine, recombinant interferon alfa, sargramostim, cyclophosphamide
Biological · Drug
Lead sponsor
St. Vincent Medical Center - Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 1, 2026, 6:34 AM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer

NCT00305760
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Cetuximab, Pancreatic tumor vaccine, Cyclophosphamide
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 1, 2026, 6:34 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Vaccine Therapy in Patients With Stages IIIB/IV Non-Small Cell Lung Cancer Who Have Finished First-Line Chemotherapy

NCT00534209
View directory record Official record
Conditions
Lung Cancer
Interventions
Allogeneic B7.1/HLA-A1, Placebo
Biological · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Hollywood, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 1, 2026, 6:34 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)

NCT04930055
View directory record Official record
Conditions
Cancer
Interventions
COVID-19 Vaccination
Biological
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
2,206 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 1, 2026, 6:34 AM EDT
Completed Not applicable Interventional

GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies

NCT00426205
View directory record Official record
Conditions
Myelodysplastic Syndrome RAEB-I or RAEB-II, Refractory Acute Myeloid Leukemia, Refractory CML Myeloid Blast Crisis
Interventions
GM-CSF secreting leukemia vaccine
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 1, 2026, 6:34 AM EDT
Terminated Phase 1 Interventional

Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies

NCT00943293
View directory record Official record
Conditions
Preleukemia, Myeloproliferative Disorders, Lymphoma, Myeloma, Graft Versus Host Disease
Interventions
Fludarabine, Melphalan, Campath
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Oct 1, 2026, 6:34 AM EDT
Completed Phase 2 Interventional Results available

Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer

NCT02648282
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Cyclophosphamide, GVAX Pancreatic Cancer Vaccine, Pembrolizumab, SBRT
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 1, 2026, 6:34 AM EDT
Completed Phase 2 Interventional Results available

Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer

NCT00389610
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
GVAX pancreas vaccine
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 1, 2026, 6:34 AM EDT